国际湿疹理事会共识:特应性皮炎系统用糖皮质激素的使用
共识认为应常规避免使用,仅在特定严重情况短期使用;多数受访者同意儿童不应使用但未达共识。结论基于专家意见,缺乏高质量证据。
要点
- 系统用糖皮质激素应常规避免,仅特殊严重情况短期使用。
- 可用于缺乏其他选择、桥接系统治疗或光疗、急性发作需立即缓解等情形。
- 儿童使用虽多数反对但未达共识,需个体化权衡。
核心结论
- 基于IEC专家意见,AD系统用糖皮质激素不鼓励常规使用,应保留给特殊情形。
研究设计与样本
- 问卷含陈述条目及视觉模拟评分,共识标准为<30%受访者倾向「强烈不同意」。
主要发现
- 共达成12项共识,包括系统用糖皮质激素一般应避免但可罕见用于严重AD的特定情形。
- 共识情形包括缺乏其他治疗选择、作为其他系统治疗或光疗的桥接、需立即缓解的急性发作、预期重大生活事件或最严重病例。
- 若使用应限于短期;多数受访者同意儿童永不使用,但该陈述未达共识。
- 若采用更严格共识标准(如<20%倾向强烈不同意),达成共识的陈述会更少。
关键数值与推荐
- 共识判定阈值:<30%受访者倾向「强烈不同意」即达成共识。
- 更严格阈值示例:<20%受访者倾向「强烈不同意」。
临床怎么用
- 临床应避免AD患者常规使用系统糖皮质激素。
- 仅考虑用于严重AD的特定情形,如缺乏其他选择、桥接治疗、急性发作需立即缓解等。
- 使用时必须限制为短期,并谨慎评估儿童使用。
局限性
- 结论基于专家意见,缺乏高质量已发表证据。
- 若采用更严格共识标准,达成共识的陈述会更少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines discourage the use of systemic corticosteroids for atopic dermatitis (AD), but their use remains widespread. OBJECTIVES: To reach consensus among an international group of AD experts on the use of systemic corticosteroids for AD. METHODS: A survey consisting of statements accompanied by visual analogue scales ranging from 'strongly disagree' to 'neutral' to 'strongly agree' was distributed to the International Eczema Council (IEC). Consensus was reached in agreement on a statement if < 30% of respondents marked to the left of 'neutral' towards 'strongly disagree'. RESULTS: Sixty of 77 (78%) IEC members participated. Consensus was reached on 12 statements, including that systemic corticosteroids should generally be avoided but can be used rarely for severe AD under certain circumstances, including a lack of other treatment options, as a bridge to other systemic therapies or phototherapy, during acute flares in need of immediate relief, in anticipation of a major life event or in the most severe cases. If used, treatment should be limited to the short term. Most respondents agreed that systemic corticosteroids should never be used in children, but consensus was not reached on that statement. The conclusions of our expert group are limited by a dearth of high-quality published evidence. If more stringent consensus criteria were applied (e.g. requiring < 20% of respondents marking towards 'strongly disagree'), consensus would have been reached on fewer statements. CONCLUSIONS: Based on expert opinion from the IEC, routine use of systemic corticosteroids for AD is generally discouraged and should be reserved for special circumstances.
引用
- Drucker AM, Eyerich K, de Bruin-Weller MS, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018. PMID: 28865094. doi:10.1111/bjd.15928
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。